Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Cash from Operations (2016 - 2025)

Historic Cash from Operations for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q2 2025 value amounting to -$40.4 million.

  • KalVista Pharmaceuticals' Cash from Operations fell 16722.28% to -$40.4 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$135.3 million, marking a year-over-year decrease of 5166.37%. This contributed to the annual value of -$152.9 million for FY2025, which is 7136.08% down from last year.
  • As of Q2 2025, KalVista Pharmaceuticals' Cash from Operations stood at -$40.4 million, which was down 16722.28% from -$39.6 million recorded in Q4 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Cash from Operations ranged from a high of -$15.1 million in Q2 2024 and a low of -$40.4 million during Q2 2025
  • For the 3-year period, KalVista Pharmaceuticals' Cash from Operations averaged around -$29.9 million, with its median value being -$27.6 million (2024).
  • As far as peak fluctuations go, KalVista Pharmaceuticals' Cash from Operations tumbled by 5046.76% in 2024, and later tumbled by 16722.28% in 2025.
  • Quarter analysis of 3 years shows KalVista Pharmaceuticals' Cash from Operations stood at -$19.8 million in 2023, then crashed by 99.96% to -$39.6 million in 2024, then decreased by 1.82% to -$40.4 million in 2025.
  • Its Cash from Operations was -$40.4 million in Q2 2025, compared to -$39.6 million in Q4 2024 and -$40.2 million in Q3 2024.